Buccal bone formation after flapless extraction: a randomized, controlled clinical trial comparing recombinant human bone morphogenetic protein 2/absorbable collagen carrier and collagen sponge alone

J Periodontol. 2014 Apr;85(4):525-35. doi: 10.1902/jop.2013.130207. Epub 2013 Jul 4.

Abstract

Background: Flapless extraction of teeth allows for undisturbed preservation of the nearby periosteum and a source of osteoprogenitor cells. Recombinant human bone morphogenetic protein 2 (rhBMP-2) has been used for different bone augmentation purposes with great osteoinductive capacity. The aim of this study is to compare the bone regenerative ability of rhBMP-2 on an absorbable collagen sponge (ACS) carrier to a collagen sponge (CS) alone in extraction sites with ≥50% buccal dehiscence.

Methods: Thirty-nine patients requiring extraction of a hopeless tooth with ≥50% buccal dehiscence were enrolled. After flapless extraction and randomization, either rhBMP-2/ACS carrier or CS alone was placed in the extraction site. After extraction, a baseline cone beam computed tomography (CBCT) scan was obtained of the site, and a similar scan was obtained 5 months postoperatively. Medical imaging and viewing software were used to compare the baseline and 5-month postoperative images of the study site and assess ridge width measurements, vertical height changes, and buccal plate regeneration.

Results: Radiographically, CBCT analysis showed that with ≥50% of buccal bone destruction, rhBMP-2/ACS was able to regenerate a portion of the lost buccal plate, maintain theoretical ridge dimensions, and allow for implant placement 5 months after extraction. The test group performed significantly (P <0.05) better in regard to clinical buccal plate regeneration (4.75 versus 1.85 mm), clinical ridge width at 5 months (6.0 versus 4.62 mm), and radiographic ridge width at 3 mm from the alveolar crest (6.17 versus 4.48 mm) after molar exclusion. There was also significantly (P <0.05) less remaining buccal dehiscence, both clinically (6.81 versus 10.0 mm) and radiographically (3.42 versus 5.16 mm), at 5 months in the test group. Significantly (P <0.05) more implants were placed in the test group without the need for additional augmentation. The mean loss in vertical ridge height (lingual/palatal) was less in the test sites but was not significantly (P = 0.514) different between the test and control groups (0.39 versus 0.64 mm).

Conclusions: rhBMP-2/ACS compared to CS alone used in flapless extraction sites with a buccal dehiscence is able to regenerate lost buccal plate, maintain theoretical ridge dimensions, and allow for implant placement 5 months later.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Absorbable Implants*
  • Adult
  • Aged
  • Alveolar Bone Loss / diagnostic imaging
  • Alveolar Bone Loss / surgery
  • Alveolar Process / diagnostic imaging
  • Alveolar Process / drug effects
  • Alveolar Ridge Augmentation / methods
  • Bone Morphogenetic Protein 2 / therapeutic use*
  • Bone Regeneration / drug effects
  • Cephalometry / methods
  • Collagen*
  • Cone-Beam Computed Tomography / methods
  • Dental Implants
  • Drug Carriers
  • Female
  • Follow-Up Studies
  • Humans
  • Imaging, Three-Dimensional / methods
  • Male
  • Middle Aged
  • Osteogenesis / drug effects*
  • Recombinant Proteins / therapeutic use
  • Tooth Extraction*
  • Tooth Socket / diagnostic imaging
  • Tooth Socket / drug effects*
  • Tooth Socket / surgery
  • Transforming Growth Factor beta / therapeutic use*
  • Young Adult

Substances

  • Bone Morphogenetic Protein 2
  • Dental Implants
  • Drug Carriers
  • Recombinant Proteins
  • Transforming Growth Factor beta
  • recombinant human bone morphogenetic protein-2
  • Collagen